Mar 21, 2017

Options exercised

PHI has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualifies for sub­scrip­tion of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). If all 252 872 shares are subscribed, the share capital of the Company will increase by 50 574 SEK (2.14 % dilution) and the equity by 3 399 088 SEK.

Ulf Avrin, board member of PHI until October 2014, has now exercised his entire option holdings, subscribing 5 484 shares at 16.50 SEK per share and 22 000 shares at 12.80 SEK per share. Through this subscription, the equity of PHI increases by 372 086 SEK. The exercise of the options implies a dilution of 0.2 % for current shareholders. After registration of the new shares at Bolagsverket (Swedish Companies Registration Office), the total number of shares in PHI will amount to 11 576 939 and the share capital to 2 315 387.80 SEK.

The above information was made public pursuant to the EU Market Abuse Regulation.

Mar 20, 2017

PHI and Malmö University receives 2.3 million kronor to detect blood-borne cancer cells

PHI and a group of experts associated with Malmö University was recently awarded a 2.3 million kronor grant by the Knowledge Foundation (KK-stiftelsen, Sweden). In close collaboration with GlycoImaging, the funded project aim to develop new methods for detecting blood-borne metastatic cancer cells.

There are today no simple methods to detect cancer – with a blood test, for example. In most cases, cancer is therefore first diagnosed when a patient consults a doctor because of the symptom the cancer develops. Sadly, this all too often results in that the cancer is treated when it is too late. Before symptoms develop, cancer cells are however often released in the blood stream. Improved detection methods of blood-borne cancer cells would make it possible to diagnose aggressive and intractable cancer with a routine blood test, before symptoms develop.

GlycoImaging is a collaboration project between PHI, Malmö University and four international research institutions. By combining PHI’s HoloMonitor technology with a new type of cancer probes, GlycoImaging aim to develop more sensitive methods to detect and diagnose cancer at an earlier stage than what is possible today. GlycoImaging is funded by a previous grant of €2.1 million from the European Commission.

“The long-term goal is to develop new and improved clinical methods to diagnose cancer. However, the same methods can readily be used in a preclinical context. The projects therefore also provide expertise and resources to in the near-term improve and expand our current HoloMonitor product line, targeting the preclinical research market”, said CEO Peter Egelberg.

To allow commercialization of the developed methods and their substantial market potential, PHI has the right to freely acquire or license the intellectual property rights which emerge in the projects.

The above information was made public pursuant to the EU Market Abuse Regulation.

Mar 2, 2017

Novel HoloMonitor-based research to be presented at cancer research annual meeting

The research results by three research groups at Northeastern University and Lund University will be presented at the American Association for Cancer Research Annual Meeting in April. Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results. The presentations will be held in connection to PHI’s exhibit at the meeting. For additional information regarding the presentations see here.

Jan 3, 2017

Japan's foremost medical institute purchases multiple HoloMonitor instruments

Japan's foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4.5 instruments for a total list price of €75 000, excluding discount. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world.

Stem cells transform into specialized cells through a series of trans­formations. The image show how blood stem cells develop into various types of blood cells.

All specialized cells in our bodies (e.g. muscle, blood and brain cells) originate from stem cells. Stem cells are unspecialized cells that under certain conditions transform into tissue- or organ-specific cells. Regenerative medicine aims to control and harness the power of stem cells to repair or replace diseased cells, tissues and organs. Cell therapies and regenerative medicine promise to treat and cure some of the most devastating and costly diseases in the world today.

Conventional drug development uses cultured cells to test a new drug before it is tested on humans. Regenerative medicine is radically different in that the cells themselves are the treatment. Traditional methods are ill-suited to study stem cells as they require the cells to be stained. The toxicity of these stains alters cell behavior and make transplantation impossible. HoloMonitor allows scientists to study how stem cells develop into specialized cells without using these toxic stains.

Articles about regenerative medicine in Japan and at University of Tokyo

The above information was made public pursuant to the EU Market Abuse Regulation.